CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials

Niu, Hao, Sanabria-Cabrera, Judith, Alvarez-Alvarez, Ismael, Robles-Diaz, Mercedes, Stankevičiūtė, Simona, Aithal, Guruprasad P., Björnsson, Einar S., Andrade, Raul J., Lucena, M. Isabel·2021·Pharmacological Research
DOI 10.1016/j.phrs.2020.105404
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.phrs.2020.105404

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 74

  1. Robles-Diaz, 2014, Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury, Gastroenterology, 147, 109, 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  2. Mallat, 1997, Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts, Dig. Dis. Sci., 42, 1486, 10.1023/A:1018870828038 · DOI
  3. Lheureux, 2009, Carnitine in the treatment of valproic acid-induced toxicity, Clin. Toxicol., 47, 101, 10.1080/15563650902752376 · DOI
  4. Katsinelos, 2000, Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: report of two cases, Eur. J. Gastroenterol. Hepatol., 12, 365, 10.1097/00042737-200012030-00017 · DOI
  5. Wree, 2011, Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury, Digestion, 84, 54, 10.1159/000322298 · DOI
  6. Mohammed Saif, 2012, Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia, Pediatr. Hematol. Oncol., 29, 627, 10.3109/08880018.2012.713083 · DOI
  7. Hu, 2019, Corticosteroid therapy in drug-induced liver injury: pros and cons, J. Dig. Dis., 20, 122, 10.1111/1751-2980.12697 · DOI
  8. Karkhanis, 2014, Steroid use in acute liver failure, Hepatology, 59, 612, 10.1002/hep.26678 · DOI
  9. Keays, 1991, Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial, BMJ, 303, 1026, 10.1136/bmj.303.6809.1026 · DOI
  10. Lee, 2009, Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure, Gastroenterology, 137, 856, 10.1053/j.gastro.2009.06.006 · DOI · Paper page
  11. Kortsalioudaki, 2008, Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure, Liver Transpl., 14, 25, 10.1002/lt.21246 · DOI
  12. Squires, 2013, Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial, Hepatology, 57, 1542, 10.1002/hep.26001 · DOI · Paper page
  13. Borlak, 2018, N-acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury, Liver Int., 38, 365, 10.1111/liv.13538 · DOI
  14. Li, 2015, The role of oxidative stress and antioxidants in liver diseases, Int. J. Mol. Sci., 16, 26087, 10.3390/ijms161125942 · DOI
  15. Chen, 2015, Drug-induced liver injury: interactions between drug properties and host factors, J. Hepatol., 63, 503, 10.1016/j.jhep.2015.04.016 · DOI
  16. Koido, 2020, Polygenic architecture informs potential vulnerability to drug-induced liver injury, Nat. Med., 26, 1541, 10.1038/s41591-020-1023-0 · DOI
  17. Singh, 2012, Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model, Hum. Exp. Toxicol., 31, 788, 10.1177/0960327111433901 · DOI
  18. Wang, 2018, Protective effects of silymarin on triptolide-induced acute hepatotoxicity in rats, Mol. Med. Rep., 17, 789
  19. Liu, 2009, Bicyclol: a novel drug for treating chronic viral hepatitis B and C, Med. Chem., 5, 29, 10.2174/157340609787049316 · DOI
  20. Yang, 2017, The anti-inflammatory activity of licorice, a widely used Chinese herb, Pharm. Biol., 55, 5, 10.1080/13880209.2016.1225775 · DOI
  21. Moher, 1998, Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?, Lancet, 352, 609, 10.1016/S0140-6736(98)01085-X · DOI · Paper page
  22. Kjaergard, 2001, Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses, Ann. Intern. Med., 135, 982, 10.7326/0003-4819-135-11-200112040-00010 · DOI
  23. Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat. Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
  24. Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 · DOI · Paper page
  25. Li, 2014, Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer, J. Int. Med. Res., 42, 906, 10.1177/0300060514527058 · DOI
  26. Chu, 2015, Role of bicyclol in preventing drug-induced liver injury in tuberculosis patients with liver disease, Int. J. Tuberc. Lung Dis., 19, 475, 10.5588/ijtld.14.0579 · DOI
  27. Hatamkhani, 2014, Carnitine for prevention of antituberculosis drug-induced hepatotoxicity: a randomized, clinical trial, J. Gastroenterol. Hepatol., 29, 997, 10.1111/jgh.12474 · DOI
  28. Yan, 2015, [Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors], Chin. J. Hepatol., 23, 204
  29. Baniasadi, 2010, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity, Eur. J. Gastroenterol. Hepatol., 22, 1235, 10.1097/MEG.0b013e32833aa11b · DOI
  30. Gu, 2015, An open-label, randomized and multi-center clinical trial to evaluate the efficacy of silibinin in preventing drug-induced liver injury, Int. J. Clin. Exp. Med., 8, 4320
  31. Luangchosiri, 2015, A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury, BMC Complement. Altern. Med., 15, 334, 10.1186/s12906-015-0861-7 · DOI
  32. Marjani, 2016, Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial, Iran. J. Pharm. Res., 15, 247
  33. Zhang, 2016, Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: a randomized controlled trial, J. Gastroenterol. Hepatol., 31, 409, 10.1111/jgh.13070 · DOI
  34. Heo, 2017, Effect of prophylactic use of silymarin on anti-tuberculosis drugs induced hepatotoxicity, Tuberc. Respir. Dis. (Seoul), 80, 265, 10.4046/trd.2017.80.3.265 · DOI
  35. Wu, 2017, [Efficacy of silibinin capsules in the prevention of liver injury induced by anti-tuberculosis drugs], Chin. J. Antituberc, 39, 757
  36. Li, 2014, The role of tiopronin for the prevention of chemotherapy-related liver toxicity in advanced colorectal cancer patients treated with mFOLFOX7: a prospective analysis, Tumori, 100, 446, 10.1177/1636.17908 · DOI
  37. Tang, 2013, [Analysis of the efficacy of bicyclol tablets in the treatment of liver injury caused by anti-tuberculosis drug], Xinxueguanbing Fangzhi Zhishi, 10, 83
  38. Wu, 2017, A multicenter and randomized controlled trial of bicyclol in the treatment of statin-induced liver injury, Med. Sci. Monit., 23, 5760, 10.12659/MSM.904090 · DOI
  39. Tang, 2012, [Magnesium isoglycyrrhizinate used in the treatment of chemotherapeutic drugs-induced acute liver dysfunction: a phase Ⅲ clinical trial], Tumor, 32, 738
  40. Wang, 2019, Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial, Liver Int., 39, 2102, 10.1111/liv.14204 · DOI · Paper page
  41. Asgarshirazi, 2017, Comparison of efficacy of folic acid and silymarin in the management of antiepileptic drug induced liver injury: a randomized clinical trial, Hepatobiliary Pancreat. Dis. Int., 16, 296, 10.1016/S1499-3872(16)60142-X · DOI
  42. Marjani, 2019, Evaluation of silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial, Gastroenterol. Hepatol. Bed Bench, 12, 138
  43. Zhou, 2018, [Clinical study on Yinzhihuang oral liquid combined with tiopronin in treatment of drug-induced liver injury], Drugs & Clinic, 33, 866
  44. Yuan, 2019, [Clinical study on Xuebijing injection combined with magnesium isoglycyrrhizinate in treatment of drug-induced liver injury], Drugs & Clinic, 34, 3102
  45. Nabi, 2017, Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study, Saudi J. Gastroenterol., 23, 169, 10.4103/1319-3767.207711 · DOI
  46. Drug-induced Liver Disease Study Group, 2015, [Guidelines for the management of drug-induced liver injury], J. Clin. Hepatol., 31, 1752
  47. Aithal, 2011, Case definition and phenotype standardization in drug-induced liver injury, Clin. Pharmacol. Ther., 89, 806, 10.1038/clpt.2011.58 · DOI
  48. Low, 2020, Drug induced liver injury: east versus West - a systematic review and meta-analysis, Clin. Mol. Hepatol., 26, 142, 10.3350/cmh.2019.1003 · DOI · Paper page
  49. Flora, 1998, Milk thistle (Silybum marianum) for the therapy of liver disease, Am. J. Gastroenterol., 93, 139, 10.1111/j.1572-0241.1998.00139.x · DOI
  50. Eminzade, 2008, Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals, Nutr. Metab. (Lond.), 5, 18, 10.1186/1743-7075-5-18 · DOI
  51. Gillessen, 2020, Silymarin as supportive treatment in liver diseases: a narrative review, Adv. Ther., 37, 1279, 10.1007/s12325-020-01251-y · DOI
  52. Ramappa, 2013, Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management, J. Clin. Exp. Hepatol., 3, 37, 10.1016/j.jceh.2012.12.001 · DOI
  53. Lee, 2016, Early monitoring for detection of antituberculous drug-induced hepatotoxicity, Korean J. Intern. Med., 31, 65, 10.3904/kjim.2016.31.1.65 · DOI
  54. Abbara, 2017, Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK, BMC Infect. Dis., 17, 231, 10.1186/s12879-017-2330-z · DOI · Paper page
  55. Tao, 2019, Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials, Can. J. Gastroenterol. Hepatol., 2019, 3192351, 10.1155/2019/3192351 · DOI
  56. Rambaldi, 2005, Milk thistle for alcoholic and/or hepatitis B or C liver diseases—a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials, Am. J. Gastroenterol., 100, 2583, 10.1111/j.1572-0241.2005.00262.x · DOI
  57. Yu, 2017, CSH guidelines for the diagnosis and treatment of drug-induced liver injury, Hepatol. Int., 11, 221, 10.1007/s12072-017-9793-2 · DOI
  58. Liu, 2005, Mechanism of protective action of bicyclol against CCl-induced liver injury in mice, Liver Int., 25, 872, 10.1111/j.1478-3231.2005.01103.x · DOI
  59. Wang, 2006, Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice, Eur. J. Pharmacol., 534, 194, 10.1016/j.ejphar.2005.12.080 · DOI
  60. Liu, 2017, Protective effect of bicyclol on anti-tuberculosis drug induced liver injury in rats, Molecules, 22, 524, 10.3390/molecules22040524 · DOI
  61. Zhao, 2020, Bicyclol attenuates acute liver injury by activating autophagy, anti-oxidative and anti-inflammatory capabilities in mice, Front. Pharmacol., 11, 463, 10.3389/fphar.2020.00463 · DOI
  62. Huang, 2014, [Pharmacoeconomic profiles of four hepatoprotective drugs used for the treatment of drug-induced liver injury], Chin. J. Hepatol., 22, 763
  63. Chalasani, 2014, ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury, Am. J. Gastroenterol., 109, 950, 10.1038/ajg.2014.131 · DOI · Paper page
  64. Xie, 2015, Anti-inflammatory activity of magnesium isoglycyrrhizinate through inhibition of phospholipase A2/arachidonic acid pathway, Inflammation, 38, 1639, 10.1007/s10753-015-0140-2 · DOI
  65. Jiang, 2017, Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury, Oncotarget, 8, 33252, 10.18632/oncotarget.16629 · DOI
  66. Cao, 2019, Protective effects of magnesium glycyrrhizinate on methotrexate-induced hepatotoxicity and intestinal toxicity may be by reducing COX-2, Front. Pharmacol., 10, 119, 10.3389/fphar.2019.00119 · DOI
  67. Hu, 2015, Efficacy and safety of acetylcysteine in "non-acetaminophen" acute liver failure: a meta-analysis of prospective clinical trials, Clin. Res. Hepatol. Gastroenterol., 39, 594, 10.1016/j.clinre.2015.01.003 · DOI
  68. Elliott, 2016, Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?, BMJ Case Rep., 2016, 10.1136/bcr-2015-213189 · DOI
  69. Chughlay, 2016, N-Acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review, Br. J. Clin. Pharmacol., 81, 1021, 10.1111/bcp.12880 · DOI
  70. Reuben, 2016, Outcomes in adults with acute liver failure between 1998 and 2013: an observational cohort study, Ann. Intern. Med., 164, 724, 10.7326/M15-2211 · DOI · Paper page
  71. Peeraphatdit, 2020, Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation, Hepatology, 72, 315, 10.1002/hep.31227 · DOI · Paper page
  72. Watkins, 2008, Using controlled clinical trials to learn more about acute drug-induced liver injury, Hepatology, 48, 1680, 10.1002/hep.22633 · DOI
  73. Danan, 1993, Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries, J. Clin. Epidemiol., 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  74. García-Cortés, 2011, Causality assessment methods in drug induced liver injury: strengths and weaknesses, J. Hepatol., 55, 683, 10.1016/j.jhep.2011.02.007 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Niu, H., Sanabria-Cabrera, J., Alvarez-Alvarez, I., Robles-Diaz, M., Stankevičiūtė, S., Aithal, G. P., Björnsson, E. S., Andrade, R. J., & Lucena, M. I.
Venue
Pharmacological Research
Publisher
Elsevier BV
Published
2021-02
Volume
164
Pages
105404
ISSN
1043-6618
DOI
10.1016/j.phrs.2020.105404
Cited by
58
References
4
Language
en
Licence
Funders
  • European Cooperation in Science and Technology (CA17112)
  • Instituto de Salud Carlos III (CM17/00243, CD20/00083, JR16/00015, PT17/0017/0020, PI18/01804, PI18/00901, PT 20/00127, B-0002-2019)
  • Federación Española de Enfermedades Raras
  • Consejería de Salud y Familias, Junta de Andalucía
  • European Regional Development Fund

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review